PUBLISHER: The Business Research Company | PRODUCT CODE: 1947120
PUBLISHER: The Business Research Company | PRODUCT CODE: 1947120
Sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing is a highly accurate molecular diagnostic technique that amplifies and detects the genetic material of pathogens responsible for sexually transmitted and vaginal infections. This method allows for rapid identification of bacteria, viruses, and other microorganisms, enabling healthcare providers to diagnose infections effectively and customize treatments.
The primary test types for STI and vaginitis PCR testing include STI PCR panels and vaginitis PCR panels. STIs are infections caused by bacteria, viruses, fungi, or parasites, primarily transmitted through sexual contact, including vaginal, anal, and oral sex. These tests cover a broad spectrum of sexually transmitted and vaginal infections and are used by various end users such as hospitals and clinics, diagnostic laboratories, and homecare or at-home testing services.
Tariffs are impacting the sti and vaginitis pcr testing market by increasing the cost of imported reagents, pcr instruments, and molecular consumables, thereby raising overall testing expenses. Diagnostic laboratories and homecare testing segments are particularly affected, with asia-pacific and emerging markets facing higher import duties on molecular diagnostics. These cost pressures have led to pricing adjustments and slower adoption in cost-sensitive regions. However, tariffs have also encouraged local manufacturing of pcr kits and reagents, fostering regional self-reliance and strengthening domestic diagnostic capabilities.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report is one of a series of new reports from The Business Research Company that provides sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market statistics, including sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry global market size, regional shares, competitors with a sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market share, detailed sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market segments, market trends and opportunities, and any further data you may need to thrive in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing industry. This sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market size has grown rapidly in recent years. It will grow from $0.68 billion in 2025 to $0.75 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing prevalence of sexually transmitted infections, limitations of traditional diagnostic methods, growing awareness of women's reproductive health, expansion of clinical diagnostic laboratories, adoption of standard pcr testing protocols.
The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market size is expected to see strong growth in the next few years. It will grow to $1.08 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to rising demand for point-of-care molecular diagnostics, technological advancements in multiplex and real-time pcr, increasing adoption of home-based testing solutions, growing investments in molecular diagnostic infrastructure, expanding screening programs for sti and vaginitis. Major trends in the forecast period include rising adoption of multiplex pcr panels for sti and vaginitis detection, increasing preference for rapid and high-sensitivity molecular diagnostics, growing demand for at-home and self-collected pcr testing kits, expansion of pcr testing in routine women's health screening, enhanced focus on early and accurate pathogen identification.
The rising frequency of sexual health screenings is expected to drive growth in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market. Sexual health screenings are medical evaluations performed to detect STIs and related conditions, enabling early diagnosis, timely treatment, and prevention of disease transmission. The increase in screenings is largely due to the global rise in STIs, which underscores the need for prompt and accurate detection to minimize complications and curb further spread. PCR testing plays a vital role in this context by allowing precise identification of pathogens, often even in asymptomatic individuals, facilitating early intervention. For instance, in June 2025, according to GOV.UK, new STI diagnoses in the UK declined by 8.8%, from 399,947 cases in 2023 to 364,750 cases in 2024, reflecting the impact of enhanced screening efforts. Therefore, the growth in sexual health screenings is propelling the expansion of the STI and vaginitis PCR testing market.
Major players in the sexually transmitted infection (STI) and vaginitis PCR testing market are developing technologies like multiplex real-time PCR assays to meet the increasing demand for fast, precise, and comprehensive pathogen detection. Multiplex PCR allows for the simultaneous amplification and identification of DNA or RNA from multiple pathogens within a single test, lowering both turnaround time and costs compared to traditional single-pathogen assays. This method also enhances sensitivity and specificity, enabling the detection of low levels of pathogen genetic material-even in co-infections-that conventional culture or microscopy techniques might overlook or detect less accurately. For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology company, introduced the Applied Biosystems TrueMark STI Select Panel, a multiplex real-time PCR assay designed to concurrently detect four prevalent STIs: Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. Intended for research purposes, this test improves clinical outcomes by offering faster, highly sensitive diagnostics while optimizing laboratory workflows, marking a notable advancement in molecular STI diagnostics.
In December 2024, OraSure Technologies, a US-based medical device and diagnostics company, acquired Sherlock Biosciences for an undisclosed sum. Through this acquisition, OraSure seeks to broaden its molecular diagnostics offerings in sexual health by incorporating Sherlock's rapid, self-collected STI testing solutions and advancing its entry into the over-the-counter diagnostics market. Sherlock Biosciences, also based in the US, specializes in PCR-based testing for sexually transmitted infections (STIs) and vaginitis.
Major companies operating in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Hologic Inc., QIAGEN N.V., ARUP Laboratories Inc., Seegene Inc., LetsGetChecked Ltd., Sansure Biotech Inc., Visby Medical Inc., R-Biopharm AG, Savyon Diagnostics Ltd., altona Diagnostics GmbH, SpeeDx Pty Ltd., CERTEST BIOTEC S.L., ALPCO Diagnostics, Atila Biosystems Inc., Ridacom Diagnostics Ltd., Sinochips Diagnostics Co Ltd., Vitassay S.L., Bioperfectus Technologies Co. Ltd.
North America was the largest region in the sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market in 2025. The regions covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market consists of revenues earned by entities by providing services such as clinical consultations, comprehensive screening tests, multiplex testing, treatment monitoring, and sample collection guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted infection (STI) and vaginitis polymerase chain reaction (PCR) testing market also includes sales of nucleic acid extraction kits, positive and negative control materials, automated PCR analyzers, and single-pathogen PCR test kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Sexually Transmitted Infection (STI) And Vaginitis Polymerase Chain Reaction (PCR) Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sexually transmitted infection (sti) and vaginitis polymerase chain reaction (pcr) testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.